LivaNova PLC is a global medical technology company that operates in over 100 countries, focusing on developing innovative solutions that enhance the lives of patients and healthcare professionals. The company is headquartered in London, United Kingdom and has a primary listing on the NASDAQ under the ticker symbol "LIVN".
LivaNova was formed in 2015 through the merger of Italian medical device manufacturer Sorin Group and American neurology firm Cyberonics. This strategic consolidation enabled LivaNova to leverage the strengths of both companies to become a leader in cardiac surgery, neuromodulation, and neuro-monitoring.
LivaNova operates through two primary business divisions: Neuromodulation and Cardiovascular.
The neuromodulation division focuses on the therapeutic solutions for patients with drug-resistant epilepsy and treatment-resistant depression. Notably, the company's VNS Therapy System is a unique treatment for people with drug-resistant epilepsy, and has been the subject of multiple clinical studies demonstrating its efficacy.
The cardiovascular division develops and manufactures a suite of solutions for cardiac surgery that includes life-saving heart-lung machines, autotransfusion systems, heart valves, and tissue heart valves. This division is known for its sutureless heart valves technology, which allows for faster, less invasive procedures.
Moreover, LivaNova is a frontrunner in treating Obstructive Sleep Apnea (OSA), a potentially serious sleep disorder. The company’s aura6000 System is an implantable device offering an alternative to traditional Continuous Positive Airway Pressure (CPAP) therapy.
LivaNova's commitment to innovation is underscored by substantial investments in research and development, which results in a robust product pipeline and a steady supply of new, cutting-edge medical technologies.
The company's mission is to enhance the life of patients through innovative medical technologies, delivering superior health economics outcomes, and providing a significantly improved quality of life.
In summary, LivaNova is a global medical technology company that works with healthcare professionals and patients worldwide to offer a broad array of innovative solutions for improved patient outcomes and reduced healthcare costs.
Despite facing challenges due to the COVID-19 pandemic, LivaNova continues to thrive due to its culture of innovation, its patient-centered focus, and its robust portfolio of medical technologies. The company is poised to continue its course as a leading global medical technology firm, dedicated to innovation and the improvement of patient quality of life.